Oral rigosertib: Additional Phase I/II data

Data from 30 evaluable MDS patients in the Phase II portion of the open-label, international Phase I/II 09-08 Study showed that twice-daily 280 mg oral rigosertib plus Vidaza azacitidine led to an ov...